Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a report released on Friday. They presently have a $80.00 price objective on the stock. Guggenheim’s price target suggests a potential upside of 106.19% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on TEVA. Mizuho reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Monday, July 25th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $75.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, July 26th. Vetr raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $60.02 price target for the company in a report on Monday, August 1st. Credit Suisse Group AG reissued a “neutral” rating on shares of Teva Pharmaceutical Industries in a report on Monday, August 1st. Finally, Jefferies Group reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 3rd. Thirteen analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $60.00.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 38.80 on Friday. The stock has a market capitalization of $39.38 billion, a P/E ratio of 22.57 and a beta of 0.73. Teva Pharmaceutical Industries has a 12-month low of $37.25 and a 12-month high of $66.55. The company has a 50-day moving average of $42.28 and a 200-day moving average of $49.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, November 15th. The company reported $1.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.29 by $0.02. The firm earned $5.56 billion during the quarter, compared to analyst estimates of $5.71 billion. Teva Pharmaceutical Industries had a net margin of 8.81% and a return on equity of 16.75%. Teva Pharmaceutical Industries’s revenue was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.35 EPS. Equities analysts expect that Teva Pharmaceutical Industries will post $5.14 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 20th. Shareholders of record on Monday, December 5th will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, December 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.51%. Teva Pharmaceutical Industries’s payout ratio is presently 50.58%.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. boosted its position in shares of Teva Pharmaceutical Industries by 11.9% in the second quarter. Franklin Resources Inc. now owns 41,211,549 shares of the company’s stock worth $2,070,095,000 after buying an additional 4,389,590 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Teva Pharmaceutical Industries by 143.7% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,700,812 shares of the company’s stock worth $1,140,263,000 after buying an additional 13,385,352 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Teva Pharmaceutical Industries by 20.9% in the third quarter. Capital Research Global Investors now owns 20,875,749 shares of the company’s stock worth $960,493,000 after buying an additional 3,609,949 shares during the last quarter. Waddell & Reed Financial Inc. boosted its position in shares of Teva Pharmaceutical Industries by 4.9% in the second quarter. Waddell & Reed Financial Inc. now owns 19,358,468 shares of the company’s stock worth $972,375,000 after buying an additional 896,033 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Teva Pharmaceutical Industries by 8.4% in the third quarter. Bank of New York Mellon Corp now owns 16,124,966 shares of the company’s stock worth $741,908,000 after buying an additional 1,256,324 shares during the last quarter. 63.16% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.